Intech Investment Management LLC bought a new stake in Coherus BioSciences, Inc. (NASDAQ:CHRS – Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with ...

Amgen’s Neulasta is set to face its first competition in the US after the FDA approved Mylan’s biosimilar version of the blockbuster cancer infection biologic. Neulasta brought in $4.5 billion ...

Napp’s Pelmeg, a biosimilar of Amgen’s cancer drug Neulasta (pegfilgrastim), has been launched in the UK following approval late last year. This is Napp’s first launch of a product developed ...

In addition to the antibiotics, Sunshine Biopharma is preparing to launch 13 more drugs in Canada in 2025, including NIOPEG®, a biosimilar of NEULASTA®, which helps reduce infection in certain ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options ...

Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta ... Amgen also has a growing biosimilar portfolio. Following our analysis of ...

WASHINGTON: U.S. regulators have declined to approve Novartis' so-called biosimilar copy of Amgen's Neulasta drug that fights infections in cancer patients, the Swiss drugmaker said on Tuesday.

AbbVie’s Humira was the top-selling drug in the world for many years. Now, its sales are eroding as doctors switch to biosimilars and new options enter the market. Immunology physicians are starting ...

After hours: 24 March at 7:53:05 pm GMT-4 Loading Chart for CHRS ...